Gamma-Synuclein Levels Are Elevated in Peritoneal Fluid of Patients with Endometriosis

Abstract

Departmental sources Background:The role of gamma-synuclein (SNCG) has been widely examined in malignant conditions due to its possible role in disease progression, but very little information is available on its theoretical function on endometriosis formation. Material/Methods:Between January 2016 and December 2016, we collected peritoneal fluid and plasma samples from 45 consecutive female patients, of which 15 were without endometriosis, 15 had minimal to mild endometriosis, and 15 had moderate to severe endometriosis. The statistical power was 0.98. We evaluated SNCG levels in the peritoneal fluid and plasma of patients diagnosed with endometriosis, and we compared them with the levels obtained from disease-free control subjects by using enzyme-linked immunosorbent assay. Results:SNCG levels were statistically significantly (1.2-fold) higher in the peritoneal fluid of patients with endometriosis compared to controls (p=0.04). We did not find a significant difference between SNCG levels in the plasma of our endometriosis patients and the control group (p=0.086). However, despite previous data showing very limited expression of SNCG in healthy tissues, we found SNCG in the peritoneal fluid of all of the patients in our healthy control group. Conclusions:Levels of SNCG were statistically significantly higher in the peritoneal fluid of patients with endometriosis compared to disease-free controls, which may indicate its possible role the formation and progression of the disease. Moreover, its biological function should be further investigated due to the conflicting results concerning its expression in healthy tissues.

Single-cell analysis of endometriosis reveals a coordinated transcriptional programme driving immunotolerance and angiogenesis across eutopic and ectopic tissues

“…In addition to attraction of immune cells, our data suggests these CCL19 + perivascular cells likely promote angiogenesis through angiopoietin expression, presumably targeting endothelial tip cells in the peritoneal microenvironment that express the corresponding receptors. In further support of these cells playing an active role in lesion vascularization and growth, it has been shown that inhibition of SNCG reduces these features in endometriosis 62 , and our data indicate SNCG is uniquely expressed by this CCL19 + perivascular population. The regulation of angiogenesis through secretion of pericyte-derived pro-angiogenic factors was previously demonstrated in in vitro proinflammatory microenvironments 63 and here we illustrate in vivo angiogenesis modulation by perivascular cells in peritoneal endometriosis.…”

Single cell analysis of endometriosis reveals a coordinated transcriptional program driving immunotolerance and angiogenesis across eutopic and ectopic tissues

“…In addition to attraction of immune cells, our data suggests these CCL19 + perivascular cells likely promote angiogenesis through angiopoietin expression, presumably targeting endothelial tip cells in the peritoneal microenvironment that express the corresponding receptors. In further support of these cells playing an active role in lesion vascularization and growth, it has been shown that inhibition of SNCG reduces these features in endometriosis 62 , and our data indicate SNCG is uniquely expressed by this CCL19 + perivascular population.…”

Identification and validation of anoikis-associated gene SNCG as a prognostic biomarker in gastric cancer

“…In contrast with SNCA and SNCB, SNCG is not only connected to neurodegenerative disorders, like Alzheimer's disease and Parkinson's disease [16], but also primarily relates to various human tumors and participates in cancer occurrence and progression [17]. For example, studies have proved that SNCG is significantly higher expressed in advanced breast cancer samples and peritoneal fluid of endometriosis patients [18], meanwhile, it can facilitate the metastasis of breast cancer [19,20]. The expression of SNCG is also elevated in high-grade serous patients.…”